Gilead ties up with generic drugmakers for COVID-19 drug supply
Share:
(Reuters) - Gilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.The pacts allow the companies - Jubilant Life Sciences Ltd , Cipla Ltd , Hetero Labs Ltd, Mylan NV and Ferozsons Laboratories Ltd - to make and sell the drug in 127 countries. (https://bit.ly/3cn7jf8)The countries consist of nearly all low-income and lower-middle income ones,..